SciClone Pharmaceuticals (NASDAQ:SCLN) Getting Somewhat Positive Media Coverage, Analysis Finds

News headlines about SciClone Pharmaceuticals (NASDAQ:SCLN) have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SciClone Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.7061312898842 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have impacted Accern’s rankings:

Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.45% on Friday, reaching $11.05. The company’s stock had a trading volume of 668,163 shares. The stock has a market cap of $576.72 million, a PE ratio of 13.64 and a beta of 1.71. SciClone Pharmaceuticals has a 1-year low of $8.55 and a 1-year high of $11.43. The company’s 50 day moving average is $10.97 and its 200-day moving average is $10.15.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. The company had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. On average, equities analysts predict that SciClone Pharmaceuticals will post $0.94 earnings per share for the current fiscal year.

Separately, Maxim Group set a $14.00 target price on SciClone Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 11th.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at

In other news, CEO Friedhelm Blobel sold 21,464 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $9.32, for a total value of $200,044.48. Following the sale, the chief executive officer now directly owns 107,692 shares in the company, valued at $1,003,689.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $10.75, for a total value of $435,375.00. Following the completion of the sale, the chief financial officer now owns 14,372 shares in the company, valued at $154,499. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 235,500 shares of company stock worth $2,479,764. Corporate insiders own 5.16% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

What are top analysts saying about SciClone Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SciClone Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit